181 related articles for article (PubMed ID: 11044651)
1. Differential activity of topotecan, irinotecan and SN-38 in fresh human tumour cells but not in cell lines.
Jonsson E; Dhar S; Jonsson B; Nygren P; Graf W; Larsson R
Eur J Cancer; 2000 Oct; 36(16):2120-7. PubMed ID: 11044651
[TBL] [Abstract][Full Text] [Related]
2. DNA-topoisomerase I, a new target for the treatment of neuroblastoma.
Vassal G; Pondarré C; Cappelli C; Terrier-Lacombe MJ; Boland I; Morizet J; Bénard J; Vénuat AM; Ardouin P; Hartmann O; Gouyette A
Eur J Cancer; 1997 Oct; 33(12):2011-5. PubMed ID: 9516844
[TBL] [Abstract][Full Text] [Related]
3. The development of camptothecin analogs in childhood cancers.
Bomgaars L; Berg SL; Blaney SM
Oncologist; 2001; 6(6):506-16. PubMed ID: 11743213
[TBL] [Abstract][Full Text] [Related]
4. An overview of topoisomerase I-targeting agents.
Arbuck SG; Takimoto CH
Semin Hematol; 1998 Jul; 35(3 Suppl 4):3-12. PubMed ID: 9779876
[TBL] [Abstract][Full Text] [Related]
5. Clinical use of topoisomerase I inhibitors in anticancer treatment.
Rodriguez-Galindo C; Radomski K; Stewart CF; Furman W; Santana VM; Houghton PJ
Med Pediatr Oncol; 2000 Oct; 35(4):385-402. PubMed ID: 11025469
[TBL] [Abstract][Full Text] [Related]
6. Preclinical development of camptothecin derivatives and clinical trials in pediatric oncology.
Vassal G; Pondarré C; Boland I; Cappelli C; Santos A; Thomas C; Lucchi E; Imadalou K; Pein F; Morizet J; Gouyette A
Biochimie; 1998 Mar; 80(3):271-80. PubMed ID: 9615866
[TBL] [Abstract][Full Text] [Related]
7. Antitumor effect of DX-8951, a novel camptothecin analog, on human pancreatic tumor cells and their CPT-11-resistant variants cultured in vitro and xenografted into nude mice.
Takiguchi S; Kumazawa E; Shimazoe T; Tohgo A; Kono A
Jpn J Cancer Res; 1997 Aug; 88(8):760-9. PubMed ID: 9330608
[TBL] [Abstract][Full Text] [Related]
8. Topoisomerase I inhibitors: the relevance of prolonged exposure for present clinical development.
Gerrits CJ; de Jonge MJ; Schellens JH; Stoter G; Verweij J
Br J Cancer; 1997; 76(7):952-62. PubMed ID: 9328159
[TBL] [Abstract][Full Text] [Related]
9. Topoisomerase I inhibitors in the treatment of colorectal cancer.
Rothenberg ML; Blanke CD
Semin Oncol; 1999 Dec; 26(6):632-9. PubMed ID: 10606256
[TBL] [Abstract][Full Text] [Related]
10. Homocamptothecin, an E-ring-modified camptothecin, exerts more potent antiproliferative activity than other topoisomerase I inhibitors in human colon cancers obtained from surgery and maintained in vitro under histotypical culture conditions.
Philippart P; Harper L; Chaboteaux C; Decaestecker C; Bronckart Y; Gordover L; Lesueur-Ginot L; Malonne H; Lavergne O; Bigg DC; da Costa PM; Kiss R
Clin Cancer Res; 2000 Apr; 6(4):1557-62. PubMed ID: 10778989
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors.
Houghton PJ; Cheshire PJ; Hallman JD; Lutz L; Friedman HS; Danks MK; Houghton JA
Cancer Chemother Pharmacol; 1995; 36(5):393-403. PubMed ID: 7634381
[TBL] [Abstract][Full Text] [Related]
12. DX-8951f, a water-soluble camptothecin analog, exhibits potent antitumor activity against a human lung cancer cell line and its SN-38-resistant variant.
Joto N; Ishii M; Minami M; Kuga H; Mitsui I; Tohgo A
Int J Cancer; 1997 Aug; 72(4):680-6. PubMed ID: 9259410
[TBL] [Abstract][Full Text] [Related]
13. Topoisomerase I inhibitors: review and update.
Rothenberg ML
Ann Oncol; 1997 Sep; 8(9):837-55. PubMed ID: 9358934
[TBL] [Abstract][Full Text] [Related]
14. Pharmacology of topoisomerase I inhibitors irinotecan (CPT-11) and topotecan.
Mathijssen RH; Loos WJ; Verweij J; Sparreboom A
Curr Cancer Drug Targets; 2002 Jun; 2(2):103-23. PubMed ID: 12188913
[TBL] [Abstract][Full Text] [Related]
15. Novel camptothecin derivative BNP1350 in experimental human ovarian cancer: determination of efficacy and possible mechanisms of resistance.
Van Hattum AH; Schlüper HM; Hausheer FH; Pinedo HM; Boven E
Int J Cancer; 2002 Jul; 100(1):22-9. PubMed ID: 12115582
[TBL] [Abstract][Full Text] [Related]
16. Clinical pharmacokinetics of irinotecan.
Chabot GG
Clin Pharmacokinet; 1997 Oct; 33(4):245-59. PubMed ID: 9342501
[TBL] [Abstract][Full Text] [Related]
17. [A symphony for the camptothecins].
Lansiaux A; Bailly C
Bull Cancer; 2003 Mar; 90(3):239-45. PubMed ID: 12801826
[TBL] [Abstract][Full Text] [Related]
18. Preclinical and phase I trials of topoisomerase I inhibitors.
Von Hoff DD; Burris HA; Eckardt J; Rothenberg M; Fields SM; Chen SF; Kuhn JG
Cancer Chemother Pharmacol; 1994; 34 Suppl():S41-5. PubMed ID: 8070026
[TBL] [Abstract][Full Text] [Related]
19. Cytotoxic activity of topotecan in human tumour cell lines and primary cultures of human tumour cells from patients.
Jonsson E; Fridborg H; Csóka K; Dhar S; Sundström C; Nygren P; Larsson R
Br J Cancer; 1997; 76(2):211-9. PubMed ID: 9231921
[TBL] [Abstract][Full Text] [Related]
20. [Topoisomerase I inhibitors. Review of phase II trials with irinotecan (CPT-11) and topotecan].
Bonneterre J
Bull Cancer; 1995 Aug; 82(8):623-8. PubMed ID: 7492818
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
